New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
05:33 EDTLLY, QGENQIAGEN, Eli Lilly collaborate to co-develop companion cancer diagnostics
QIAGEN N.V. (QGEN) announced a collaboration with Eli Lilly (LLY) to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on QIAGEN's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.
News For QGEN;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
09:29 EDTLLYEli Lilly sees ForEx to have a negative impact of 4c in 2015 EPS
Subscribe for More Information
07:20 EDTLLYEli Lilly CEO Lechleiter says currency fluctuations hitting topline
Subscribe for More Information
06:38 EDTLLYEli Lilly reports Q4 Cialis sales $622.4M vs. $588.3M last year
Subscribe for More Information
06:30 EDTLLYEli Lilly FY15 EPS guidance does not include 12c potential charge
Subscribe for More Information
06:28 EDTLLYEli Lilly backs FY15 EPS view of $3.10-$3.20, consensus $3.18
Lowers FY15 revenue guidance to $19.5B-$20B from $20.3B-$20.8B, consensus $20.67B.
06:26 EDTLLYEli Lilly reports Q4 EPS 75c, consensus 74c
Subscribe for More Information
January 29, 2015
15:37 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
13:36 EDTLLYEli Lilly volatility elevated into Q4 and outlook
Subscribe for More Information
13:29 EDTLLYEarnings Preview: Eli Lilly to report Q4 results amid new product launches
Subscribe for More Information
12:00 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.
January 28, 2015
16:14 EDTQGENQIAGEN sees Q1 adjusted EPS 22c-23c, consensus 25c
Subscribe for More Information
16:13 EDTQGENQIAGEN sees adjusted sales, EPS growing at constant exchange rates
Subscribe for More Information
16:11 EDTQGENQIAGEN reports Q4 adjusted EPS 25c, consensus 30c
Subscribe for More Information
15:37 EDTQGENNotable companies reporting after market close
Subscribe for More Information
08:13 EDTQGENQIAGEN management to meet with Evercore ISI
Subscribe for More Information
January 27, 2015
16:06 EDTQGENQIAGEN launches monitor to track immune function in organ transplant patients
QIAGEN N.V. announced the commercial launch of QuantiFERON Monitor, a diagnostic for monitoring immune function. QIAGEN is launching QuantiFERON Monitor in Europe as a CE-marked in-vitro diagnostic. Primary applications include monitoring of immune function in solid organ transplant recipients. In North America and other markets, QFM is available for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
15:04 EDTQGENQIAGEN management to meet with Leerink
Meeting to be held in New York on February 3 hosted by Leerink.
January 21, 2015
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use